Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Renal Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Renal Cancer
    Sorafenib Safe and Effective in Elderly Patients With Metastatic Renal Cell Carcinoma: Presented at EMUC - (DGDispatch)
    Antiangiogenesis Agent Pazopanib Well Tolerated, Offers Clinical Benefits in Patients With Advanced Renal Cell Carcinoma: Presented at EMUC - (DGDispatch)
    Cediranib Demonstrates Safe, Well Tolerated Antitumour Activity in Patients With Advanced Renal Cell Carcinoma: Presented at EMUC - (DGDispatch)
    Interleukin-2 Plus Sorafenib Combination Improves Disease Control Over Sorafenib Alone in Advanced Renal Cell Carcinoma: Presented at EMUC - (DGDispatch)
    TopAbstracts in Renal Cancer 11/25/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Renal Cancer

    Webcasts/CME archive

     Recent cases - Renal Cancer
      Synchronous Lingual and Thyroid Metastasis from Renal Cell Carcinoma
      Granulocytosis and Thrombocytosis in Renal Cell Carcinoma: A Pro-Inflammatory Cytokine Response Originating in the Tumour
      Xp11.2 Translocation Renal Cell Carcinoma Occurring During Pregnancy with a Novel Translocation Involving Chromosome 19: A Case Report with Review of the Literature
      Stauffer's Syndrome as a Prominent Manifestation of Renal Cancer: A Case Report
      Oral Cavity Metastasis of Renal Cell Carcinoma: A Case Report

      Cases archive
        




      my personal edition > renal cancer > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Gemcitabine/5-Fluorouracil Does Not Appear To Be More Effective In One Metastatic Renal Cancer Subgroup Over Another

      A DGReview of :"Prognostic Factors for Survival With Gemcitabine Plus 5-fluorouracil Based Regimens for Metastatic Renal Cancer"
      Journal of Urology

      10/01/2003
      By Emma Hitt, PhD


      In patients with metastatic renal cancer, gemcitabine/5-fluorouracil (5-FU) provides a modest improvement over traditional chemotherapy approaches, but no clearly identifiable subgroup is most likely to benefit from this regimen, new research suggests.

      According to the researchers, therapies for patients with metastatic renal cell cancer are limited. Immunotherapy with interleukin-2 and/or interferon benefits only a minority of patients, and no standard therapy exists for patients in whom first-line immunotherapy fails.

      Combination gemcitabine/5-FU may have activity in metastatic renal cell cancer, with previous clinical trials suggesting a combined overall response rate of about 14% and possibly a prolonged time to progression compared to other chemotherapy treatments.

      To identify the subgroups that may benefit the most from gemcitabine/5-FU, Walter M. Stadler, MD, with the University of Chicago, Illinois, United States, and colleagues analysed data on 153 patients with metastatic renal cell cancer from 1 phase I and 4 phase II trials.

      Of these patients, 15 partial and 1 complete responses were observed for an overall response rate of 10%. Median survival was 12.5 months (95% confidence interval 10.7 to 15.2).

      The researchers found that independent risk factors for poor survival included poor performance status, absent prior nephrectomy, 3 or more metastatic sites, decreased albumin, and elevated alkaline phosphatase, while sarcomatoid features and elevated calcium had borderline significance.

      According to the researchers, these observations are "similar to those reported previously in other studies and suggest that they are consistent prognostic factors for metastatic renal cancer and not specific to the underlying treatment."

      They also note that the current study supports previous observations of a modest survival benefit with gemcitabine/5-fluorouracil, although definitive conclusions would require a randomised study.

      "Perhaps the most surprising observation was that lack of prior nephrectomy maintained independent prognostic importance on multivariate analysis," Dr. Stadler and colleagues note. They suggest that this "raises the hypothesis that nephrectomy is an important part of therapy for patients with metastatic disease even in those not treated with immunotherapy."

      J Urol 2003;170:4 Pt 1:1141-1145. "Prognostic Factors for Survival With Gemcitabine Plus 5-fluorouracil Based Regimens for Metastatic Renal Cancer"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send